

What is claimed is:

1. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to sequences selected from the group consisting of: SEQ ID NO:59 to SEQ ID NO:116; said nucleic acid molecule encoding at least a portion of nGPCR-x.
2. The isolated nucleic acid molecule of claim 1 comprising a sequence that encodes a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:59 to SEQ ID NO:116.
3. The isolated nucleic acid molecule of claim 1 comprising a sequence homologous to a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:58.
4. The isolated nucleic acid molecule of claim 1 comprising a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:58.
5. The isolated nucleic acid molecule of claim 1 wherein said nucleic acid molecule is DNA.
6. The isolated nucleic acid molecule of claim 1 wherein said nucleic acid molecule is RNA.
7. An expression vector comprising a nucleic acid molecule of any one of claims 1 to 4.
8. The expression vector of claim 7 wherein said nucleic acid molecule comprises a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:58.
9. The expression vector of claim 7 wherein said vector is a plasmid.
10. The expression vector of claim 7 wherein said vector is a viral particle.
11. The expression vector of claim 10 wherein said vector is selected from the group consisting of adenoviruses, baculoviruses, parvoviruses, herpesviruses, poxviruses, adeno-associated viruses, Semliki Forest viruses, vaccinia viruses, and retroviruses.

12. The expression vector of claim 7 wherein said nucleic acid molecule is operably connected to a promoter selected from the group consisting of simian virus 40, mouse mammary tumor virus, long terminal repeat of human immunodeficiency virus, maloney virus, cytomegalovirus immediate early promoter, Epstein Barr virus, rous sarcoma virus, human actin, human myosin, human hemoglobin, human muscle creatine, and human metallothionein.
13. A host cell transformed with an expression vector of claim 7.
14. The transformed host cell of claim 13 wherein said cell is a bacterial cell.
15. The transformed host cell of claim 14 wherein said bacterial cell is *E. coli*.
16. The transformed host cell of claim 13 wherein said cell is yeast.
17. The transformed host cell of claim 16 wherein said yeast is *S. cerevisiae*.
18. The transformed host cell of claim 13 wherein said cell is an insect cell.
19. The transformed host cell of claim 18 wherein said insect cell is *S. frugiperda*.
20. The transformed host cell of claim 13 wherein said cell is a mammalian cell.
21. The transformed host cell of claim 20 wherein mammalian cell is selected from the group consisting of chinese hamster ovary cells, HeLa cells, African green monkey kidney cells, human HEK-293 cells, and murine 3T3 fibroblasts.
22. An isolated nucleic acid molecule comprising at least 10 nucleotides, said nucleic acid molecule comprising a nucleotide sequence complementary to at least a portion of a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:58.
23. The nucleic acid molecule of claim 22 wherein said molecule is an antisense oligonucleotide directed to a region of a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:58.

24. The nucleic acid molecule of claim 23 wherein said oligonucleotide is directed to a regulatory region of a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:58.

25. A composition comprising a nucleic acid molecule of any one of claims 1 to 4 or 22 and an acceptable carrier or diluent.

26. A composition comprising a recombinant expression vector of claim 7 and an acceptable carrier or diluent.

27. A method of producing a polypeptide that comprises a sequence selected from the group of sequences consisting SEQ ID NO:59 to SEQ ID NO:116, and homologs thereof, said method comprising the steps of:

- a) introducing a recombinant expression vector of claim 8 into a compatible host cell;
- b) growing said host cell under conditions for expression of said polypeptide; and
- c) recovering said polypeptide.

28. The method of claim 27 wherein said host cell is lysed and said polypeptide is recovered from the lysate of said host cell.

29. The method of claim 27 wherein said polypeptide is recovered by purifying the culture medium without lysing said host cell.

30. An isolated polypeptide encoded by a nucleic acid molecule of claim 1.

31. The polypeptide of claim 30 wherein said polypeptide comprises a sequence selected from the group of sequences consisting of SEQ ID NO:59 to SEQ ID NO:116.

32. The polypeptide of claim 30 wherein said polypeptide comprises an amino acid sequence homologous to a sequence selected from the group of sequences consisting of SEQ ID NO:59 to SEQ ID NO:116.

33. The polypeptide of claim 30 wherein said sequence homologous to a sequence selected from the group of sequences consisting of SEQ ID NO:59 to SEQ ID NO:116 comprises at least one conservative amino acid substitution compared to the sequences in the group of sequences consisting of SEQ ID NO:59 to SEQ ID NO:116.
34. The polypeptide of claim 30 wherein said polypeptide comprises an allelic variant of a polypeptide with a sequence selected from the group of sequences consisting of SEQ ID NO:59 to SEQ ID NO:116.
35. A composition comprising a polypeptide of claim 34 and an acceptable carrier or diluent.
36. An isolated antibody which binds to an epitope on a polypeptide of claim 30.
37. The antibody of claim 36 wherein said antibody is a monoclonal antibody.
38. A composition comprising an antibody of claim 36 and an acceptable carrier or diluent.
39. A method of inducing an immune response in a mammal against a polypeptide of claim 30 comprising administering to said mammal an amount of said polypeptide sufficient to induce said immune response.
40. A method for identifying a compound which binds nGPCR-x comprising the steps of:
- a) contacting nGPCR-x with a compound; and
 - b) determining whether said compound binds nGPCR-x.
41. The method of claim 40 wherein the nGPCR-x comprises an amino acid sequence selected from the group consisting of SEQ ID NO:59 to SEQ ID NO:116.
42. The method of claim 40 wherein binding of said compound to nGPCR-x is determined by a protein binding assay.
43. The method of claim 40 wherein said protein binding assay is selected from the group consisting of a gel-shift assay, Western blot, radiolabeled competition assay, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross linking, interaction trap/two-hybrid analysis, southwestern analysis, and ELISA.

44. A compound identified by the method of claim 40.
45. A method for identifying a compound which binds a nucleic acid molecule encoding nGPCR-x comprising the steps of:
- a) contacting said nucleic acid molecule encoding nGPCR-x with a compound; and
 - b) determining whether said compound binds said nucleic acid molecule.
46. The method of claim 45 wherein binding is determined by a gel-shift assay.
47. A compound identified by the method of claim 45.
48. A method for identifying a compound which modulates the activity of nGPCR-x comprising the steps of:
- a) contacting nGPCR-x with a compound; and
 - b) determining whether nGPCR-x activity has been modulated.
49. The method of claim 48 wherein the nGPCR-x comprises an amino acid sequence selected from the group consisting of SEQ ID NO:59 to SEQ ID NO:116.
50. The method of claim 48 wherein said activity is neuropeptide binding.
51. The method of claim 48 wherein said activity is neuropeptide signaling.
52. A compound identified by the method of claim 48.
53. A method of identifying an animal homolog of nGPCR-x comprising the steps:
- a) comparing the nucleic acid sequences of the animal with a sequence selected from the group of sequence consisting of SEQ ID NO:1 to SEQ ID NO:58, and portions thereof, said portions being at least 10 nucleotides; and
 - b) identifying nucleic acid sequences of the animal that are homologous to said sequence selected from the group sequence consisting of SEQ ID NO:1 to SEQ ID NO:58, and portions thereof, said portions comprising at least 10 nucleotides.

54. The method of claim 53 wherein comparing the nucleic acid sequences of the animal with a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:58, and portions thereof, said portions being at least 10 nucleotides, is performed by DNA hybridization.

55. The method of claim 53 wherein comparing the nucleic acid sequences of the animal with a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:58, and portions thereof, said portions being at least 10 nucleotides, is performed by computer homology search.

56. A method of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor, comprising the steps of:

(a) assaying nucleic acid of a human subject to determine a presence or an absence of a mutation altering an amino acid sequence, expression, or biological activity of at least one nGPCR-x that is expressed in the brain, wherein the nGPCR-x comprises an amino acid sequence selected from the group consisting of SEQ ID NO:59 to SEQ ID NO:116, and allelic variants thereof, and wherein the nucleic acid corresponds to a gene encoding the nGPCR-x; and

(b) diagnosing the disorder or predisposition from the presence or absence of said mutation, wherein the presence of a mutation altering the amino acid sequence, expression, or biological activity of the nGPCR-x in the nucleic acid correlates with an increased risk of developing the disorder.

57. A method according to claim 56, wherein the disease is a mental disorder.

58. A method according to claim 56, wherein the assaying step comprises at least one procedure selected from the group consisting of:

a) comparing nucleotide sequences from the human subject and reference sequences and determining a difference of at least a nucleotide of at least one codon between the nucleotide sequences from the human subject that encodes a nGPCR-x reference sequence;

(b) performing a hybridization assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences;

(c) performing a polynucleotide migration assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences; and

(d) performing a restriction endonuclease digestion to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences.

59. A method according to claim 58 wherein the assaying step comprises: performing a polymerase chain reaction assay to amplify nucleic acid comprising nGPCR-x coding sequence, and determining nucleotide sequence of the amplified nucleic acid.

60. A method of screening for an nGPCR-x hereditary mental disorder genotype in a human patient, comprising the steps of:

(a) providing a biological sample comprising nucleic acid from said patient, said nucleic acid including sequences corresponding to alleles of nGPCR-x; and

(b) detecting the presence of one or more mutations in the nGPCR-x allele;

wherein the presence of a mutation in a nGPCR-x allele is indicative of a hereditary mental disorder genotype.

61. The method according to claim 60 wherein said biological sample is a cell sample.

62. The method according to claim 60 wherein said detecting the presence of a mutation comprises sequencing at least a portion of said nucleic acid, said portion comprising at least one codon of said nGPCR-x allele, said portion comprising at least 10 nucleotides.

63. The method according to claim 60 wherein said nucleic acid is DNA.

64. The method according to claim 60 wherein said nucleic acid is RNA.

65. A kit for screening a human subject to diagnose a mental disorder or a genetic predisposition therefor, comprising, in association:

(a) an oligonucleotide useful as a probe for identifying polymorphisms in a human nGPCR-x gene, the oligonucleotide comprising 6-50 nucleotides in a sequence that is identical or complementary to a sequence of a wild type human nGPCR-x gene sequence or

nGPCR-x coding sequence, except for one sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide substitution; and

(b) a media packaged with the oligonucleotide, said media containing information for identifying polymorphisms that correlate with mental disorder or a genetic predisposition therefor, the polymorphisms being identifiable using the oligonucleotide as a probe.

66. A method of identifying a nGPCR-x allelic variant that correlates with a mental disorder, comprising the steps of:

(a) providing a biological sample comprising nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny;

(b) detecting in the nucleic acid the presence of one or more mutations in an nGPCR-x that is expressed in the brain, wherein the nGPCR-x comprises an amino acid sequence selected from the group consisting of SEQ ID NO:59 to SEQ ID NO:116, and allelic variants thereof, and wherein the nucleic acid includes sequence corresponding to the gene or genes encoding nGPCR-x;

wherein the one or more mutations detected indicates an allelic variant that correlates with a mental disorder.

67. A purified and isolated polynucleotide comprising a nucleotide sequence encoding a nGPCR-x allelic variant identified according to claim 66.

68. A host cell transformed or transfected with a polynucleotide according to claim 67 or with a vector comprising the polynucleotide.

69. A purified polynucleotide comprising a nucleotide sequence encoding nGPCR-x of a human with a mental disorder;

wherein said polynucleotide hybridizes to the complement of a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:58 under the following hybridization conditions:

(a) hybridization for 16 hours at 42°C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and

(b) washing 2 times for 30 minutes at 60°C in a wash solution comprising 0.1x SSC and 1% SDS; and

wherein the polynucleotide that encodes nGPCR-x amino acid sequence of the human differs from the sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:58 by at least one residue.

70. A vector comprising a polynucleotide according to claim 69.

71. A host cell that has been transformed or transfected with a polynucleotide according to claim 69 and that expresses the nGPCR-x protein encoded by the polynucleotide.

72. A host cell according to claim 71 that has been co-transfected with a polynucleotide encoding the nGPCR-x amino acid sequence set forth in a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:58 and that expresses the nGPCR-x protein having the amino acid sequence set forth in SEQ ID NO:59 to SEQ ID NO:116.

73. A method for identifying a modulator of biological activity of nGPCR-x comprising the steps of:

a) contacting a cell according to claim 72 in the presence and in the absence of a putative modulator compound;

b) measuring nGPCR-x biological activity in the cell;
wherein decreased or increased nGPCR-x biological activity in the presence versus absence of the putative modulator is indicative of a modulator of biological activity.

74. A method to identify compounds useful for the treatment of a mental disorder, said method comprising the steps of:

(a) contacting a composition comprising nGPCR-x with a compound suspected of binding nGPCR-x;

(b) detecting binding between nGPCR-x and the compound suspected of binding nGPCR-x;

wherein compounds identified as binding nGPCR-x are candidate compounds useful for the treatment of a mental disorder.

75. A method for identifying a compound useful as a modulator of binding between nGPCR-x and a binding partner of nGPCR-x comprising the steps of:

(a) contacting the binding partner and a composition comprising nGPCR-x in the presence and in the absence of a putative modulator compound;

(b) detecting binding between the binding partner and nGPCR-x; wherein decreased or increased binding between the binding partner and nGPCR-x in the presence of the putative modulator, as compared to binding in the absence of the putative modulator is indicative a modulator compound useful for the treatment of a mental disorder.

76. A method according to claim 74 or 75 wherein the composition comprises a cell expressing nGPCR-x on its surface.

77. A method according to claim 76 wherein the composition comprises a cell transformed or transfected with a polynucleotide that encodes nGPCR-x.

78. A method of purifying a G protein from a sample containing said G protein comprising the steps of:

- a) contacting said sample with a polypeptide of claim 1 for a time sufficient to allow said G protein to form a complex with said polypeptide;
- b) isolating said complex from remaining components of said sample;
- c) maintaining said complex under conditions which result in dissociation of said G protein from said polypeptide; and
- d) isolating said G protein from said polypeptide.

79. The method of claim 78 wherein said sample comprises an amino acid sequence selected from the group of sequences consisting of SEQ ID NO:59 to SEQ ID NO:116.

80. The method of claim 78 wherein said polypeptide comprises an amino acid sequence homologous to a sequence selected from the group of sequences consisting of SEQ ID NO:59 to SEQ ID NO:116.

81. The method of claim 78 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:59 to SEQ ID NO:116.

82. The isolated nucleic acid molecule of claim 1 comprising a sequence that encodes a polypeptide comprising a sequence of SEQ ID NO:67.

83. The isolated nucleic acid molecule of claim 1 comprising a sequence homologous to a sequence of SEQ ID NO:9.
84. The isolated nucleic acid molecule of claim 1 comprising a sequence of SEQ ID NO: 9.
85. An expression vector comprising a nucleic acid molecule of any one of claims 82 to 84.
86. An isolated nucleic acid molecule comprising at least 10 nucleotides, said nucleic acid molecule comprising a nucleotide sequence complementary to at least a portion of a sequence of SEQ ID NO:9.
87. The nucleic acid molecule of claim 86 wherein said molecule is an antisense oligonucleotide directed to a region of a sequence of SEQ ID NO:9.
88. The nucleic acid molecule of claim 87 wherein said oligonucleotide is directed to a regulatory region of a sequence of SEQ ID NO:9.
89. A method of producing a polypeptide that comprises a sequence of SEQ ID NO:67, and homologs thereof, said method comprising the steps of:
- a) introducing a recombinant expression vector of claim 85 into a compatible host cell;
 - b) growing said host cell under conditions for expression of said polypeptide; and
 - c) recovering said polypeptide.
90. An isolated polypeptide encoded by a nucleic acid molecule of claim 82.
91. The polypeptide of claim 90 wherein said polypeptide comprises a sequence of SEQ ID NO:67.
92. The polypeptide of claim 90 wherein said polypeptide comprises an amino acid sequence homologous to a sequence of SEQ ID NO:67.
93. An isolated antibody which binds to an epitope on a polypeptide of claim 90.

94. The antibody of claim 93 wherein said antibody is a monoclonal antibody.
95. A method of inducing an immune response in a mammal against a polypeptide of claim 90 comprising administering to said mammal an amount of said polypeptide sufficient to induce said immune response.
96. A method for identifying a compound which binds nGPCR-93 comprising the steps of:
- a) contacting nGPCR-93 with a compound; and
 - c) determining whether said compound binds nGPCR-93.
97. The method of claim 96 wherein nGPCR-93 comprises an amino acid sequence of SEQ ID NO:67.
98. The method of claim 96 wherein binding of said compound to nGPCR-x is determined by a protein binding assay.
99. A compound identified by the method of claim 96.
100. A method for identifying a compound which binds a nucleic acid molecule encoding nGPCR-93 comprising the steps of:
- a) contacting said nucleic acid molecule encoding nGPCR-93 with a compound; and
 - b) determining whether said compound binds said nucleic acid molecule.
101. The method of claim 100 wherein binding is determined by a gel-shift assay. ✓
102. A compound identified by the method of claim 100.
103. A method for identifying a compound which modulates the activity of nGPCR-93 comprising the steps of:
- a) contacting nGPCR-93 with a compound; and
 - b) determining whether nGPCR-93 activity has been modulated.
104. The method of claim 103 wherein the nGPCR-x comprises an amino acid sequence of SEQ ID NO:67.

105. The method of claim 103 wherein said activity is neuropeptide binding.
106. The method of claim 103 wherein said activity is neuropeptide signaling.
107. A compound identified by the method of claim 103.
108. 5A method of identifying an animal homolog of nGPCR-93 comprising the steps:
- a) comparing the nucleic acid sequences of the animal with a sequence of SEQ ID NO:9, and portions thereof, said portions being at least 10 nucleotides; and
 - b) identifying nucleic acid sequences of the animal that are homologous to said sequence of SEQ ID NO:9, and portions thereof, said portions comprising at least 10 nucleotides.
109. The method of claim 108 wherein comparing the nucleic acid sequences of the animal with a sequence of SEQ ID NO:9, and portions thereof, said portions being at least 10 nucleotides, is performed by DNA hybridization.
110. The method of claim 108 wherein comparing the nucleic acid sequences of the animal with a sequence of SEQ ID NO:9, and portions thereof, said portions being at least 10 nucleotides, is performed by computer homology search.
111. A method of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor, comprising the steps of:
- (a) assaying nucleic acid of a human subject to determine a presence or an absence of a mutation altering an amino acid sequence, expression, or biological activity of at least one nGPCR-x that is expressed in the brain, wherein the nGPCR-x comprises an amino acid sequence of SEQ ID NO:67, and allelic variants thereof, and wherein the nucleic acid corresponds to a gene encoding the nGPCR-x; and
 - (b) diagnosing the disorder or predisposition from the presence or absence of said mutation, wherein the presence of a mutation altering the amino acid sequence, expression, or biological activity of the nGPCR-x in the nucleic acid correlates with an increased risk of developing the disorder.
112. A method according to claim 111, wherein the disease is a mental disorder.

113. A purified polynucleotide comprising a nucleotide sequence encoding nGPCR-x of a human with a mental disorder;

wherein said polynucleotide hybridizes to the complement of a sequence of SEQ ID NO:9 under the following hybridization conditions:

(a) hybridization for 16 hours at 42°C in a hybridization solution comprising

50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and

(b) washing 2 times for 30 minutes at 60°C in a wash solution comprising 0.1x

SSC and 1% SDS; and

wherein the polynucleotide that encodes nGPCR-x amino acid sequence of the human differs from the sequence of SEQ ID NO:9 by at least one residue.

114. A vector comprising a polynucleotide according to claim 113.

115. A host cell that has been transformed or transfected with a polynucleotide according to claim 113 and that expresses the nGPCR-x protein encoded by the polynucleotide.

116. A host cell according to claim 115 that has been co-transfected with a polynucleotide encoding the nGPCR-x amino acid sequence set forth in a sequence of SEQ ID NO:9 and that expresses the nGPCR-x protein having the amino acid sequence set forth in SEQ ID NO:67.

117. A method for identifying a modulator of biological activity of nGPCR-93 comprising the steps of:

a) contacting a cell according to claim 116 in the presence and in the absence of a putative modulator compound;

b) measuring nGPCR-93 biological activity in the cell;

wherein decreased or increased nGPCR-93 biological activity in the presence versus absence of the putative modulator is indicative of a modulator of biological activity.

118. A method for identifying a compound useful as a modulator of binding between nGPCR-93 and a binding partner of nGPCR-93 comprising the steps of:

(a) contacting the binding partner and a composition comprising

nGPCR-93 in the presence and in the absence of a putative modulator compound;

(b) detecting binding between the binding partner and nGPCR-93;

1. 1. The first part of the report
 2. 2. The second part of the report
 3. 3. The third part of the report
 4. 4. The fourth part of the report
 5. 5. The fifth part of the report
 6. 6. The sixth part of the report
 7. 7. The seventh part of the report
 8. 8. The eighth part of the report
 9. 9. The ninth part of the report
 10. 10. The tenth part of the report
 11. 11. The eleventh part of the report
 12. 12. The twelfth part of the report
 13. 13. The thirteenth part of the report
 14. 14. The fourteenth part of the report
 15. 15. The fifteenth part of the report
 16. 16. The sixteenth part of the report
 17. 17. The seventeenth part of the report
 18. 18. The eighteenth part of the report
 19. 19. The nineteenth part of the report
 20. 20. The twentieth part of the report
 21. 21. The twenty-first part of the report
 22. 22. The twenty-second part of the report
 23. 23. The twenty-third part of the report
 24. 24. The twenty-fourth part of the report
 25. 25. The twenty-fifth part of the report
 26. 26. The twenty-sixth part of the report
 27. 27. The twenty-seventh part of the report
 28. 28. The twenty-eighth part of the report
 29. 29. The twenty-ninth part of the report
 30. 30. The thirtieth part of the report
 31. 31. The thirty-first part of the report
 32. 32. The thirty-second part of the report
 33. 33. The thirty-third part of the report
 34. 34. The thirty-fourth part of the report
 35. 35. The thirty-fifth part of the report
 36. 36. The thirty-sixth part of the report
 37. 37. The thirty-seventh part of the report
 38. 38. The thirty-eighth part of the report
 39. 39. The thirty-ninth part of the report
 40. 40. The fortieth part of the report
 41. 41. The forty-first part of the report
 42. 42. The forty-second part of the report
 43. 43. The forty-third part of the report
 44. 44. The forty-fourth part of the report
 45. 45. The forty-fifth part of the report
 46. 46. The forty-sixth part of the report
 47. 47. The forty-seventh part of the report
 48. 48. The forty-eighth part of the report
 49. 49. The forty-ninth part of the report
 50. 50. The fiftieth part of the report
 51. 51. The fifty-first part of the report
 52. 52. The fifty-second part of the report
 53. 53. The fifty-third part of the report
 54. 54. The fifty-fourth part of the report
 55. 55. The fifty-fifth part of the report
 56. 56. The fifty-sixth part of the report
 57. 57. The fifty-seventh part of the report
 58. 58. The fifty-eighth part of the report
 59. 59. The fifty-ninth part of the report
 60. 60. The sixtieth part of the report
 61. 61. The sixty-first part of the report
 62. 62. The sixty-second part of the report
 63. 63. The sixty-third part of the report
 64. 64. The sixty-fourth part of the report
 65. 65. The sixty-fifth part of the report
 66. 66. The sixty-sixth part of the report
 67. 67. The sixty-seventh part of the report
 68. 68. The sixty-eighth part of the report
 69. 69. The sixty-ninth part of the report
 70. 70. The seventieth part of the report
 71. 71. The seventy-first part of the report
 72. 72. The seventy-second part of the report
 73. 73. The seventy-third part of the report
 74. 74. The seventy-fourth part of the report
 75. 75. The seventy-fifth part of the report
 76. 76. The seventy-sixth part of the report
 77. 77. The seventy-seventh part of the report
 78. 78. The seventy-eighth part of the report
 79. 79. The seventy-ninth part of the report
 80. 80. The eightieth part of the report
 81. 81. The eighty-first part of the report
 82. 82. The eighty-second part of the report
 83. 83. The eighty-third part of the report
 84. 84. The eighty-fourth part of the report
 85. 85. The eighty-fifth part of the report
 86. 86. The eighty-sixth part of the report
 87. 87. The eighty-seventh part of the report
 88. 88. The eighty-eighth part of the report
 89. 89. The eighty-ninth part of the report
 90. 90. The ninetieth part of the report
 91. 91. The ninety-first part of the report
 92. 92. The ninety-second part of the report
 93. 93. The ninety-third part of the report
 94. 94. The ninety-fourth part of the report
 95. 95. The ninety-fifth part of the report
 96. 96. The ninety-sixth part of the report
 97. 97. The ninety-seventh part of the report
 98. 98. The ninety-eighth part of the report
 99. 99. The ninety-ninth part of the report
 100. 100. The hundredth part of the report

120. A method according to claim 119 wherein the composition comprises a cell transformed or transfected with a polynucleotide that encodes nGPCR-93.

the steps of:

- contacting said sample with a polypeptide of claim 90 for a time sufficient to allow said G protein to form a complex with said polypeptide;
- isolating said complex from remaining components of said sample;
- maintaining said complex under conditions which result in dissociation of said G protein from said polypeptide; and
- isolating said G protein from said polypeptide.

123. The method of claim 121 wherein said polypeptide comprises an amino acid sequence homologous to a sequence of SEQ ID NO:67.

124. The method of claim 121 wherein said polypeptide comprises an amino acid sequence of
SEQ ID NO:67.